Literature DB >> 22440

Receptor affinity and pharmacological potency of a series of narcotic analgesic, anti-diarrheal and neuroleptic drugs.

K D Stahl, W van Bever, P Janssen, E J Simon.   

Abstract

A series of 26 drugs was tested for in vitro binding to opiate receptors in the presence and absence of 0.1 M NaCl. The results were correlated with assays for in vivo pharmacological potency. Highly significant correlation was found between binding in the presence and absence of sodium ions and analgesic potency. For 10 drugs tested for anti-diarrheal potency significant correlation was observed with binding to brain opiate receptors when binding was carried out in sodium-containing medium. These data add support to the hypothesis that stereospecific opiate binding sites are pharmacological receptors which mediate analgesia and anti-diarrheal action. We found that neuroleptics can bind to opiate receptors with affinities in the micromolar range, in agreement with reports by others. The anti-diarrheal compound loperamide exhibits no significant central opiate effects but binds to opiate receptors from brain in vitro with high affinity. Evidency is presented suggesting that the lack of specific analgesic effect is the result of poor penetration through the blood--brain barrier. Our results lend further support to the similarity of opiate receptors in the brain and in the intestinal tract.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 22440     DOI: 10.1016/0014-2999(77)90334-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

1.  Control of guinea pig intestinal electrolyte secretion by a delta-opiate receptor.

Authors:  J F Kachur; R J Miller; M Field
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

2.  The physiological relevance of low agonist affinity binding at opioid mu-receptors.

Authors:  J A Carroll; J S Shaw; A D Wickenden
Journal:  Br J Pharmacol       Date:  1988-06       Impact factor: 8.739

3.  Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function.

Authors:  Neva Lazarova; Sami S Zoghbi; Jinsoo Hong; Nicholas Seneca; Ed Tuan; Robert L Gladding; Jeih-San Liow; Andrew Taku; Robert B Innis; Victor W Pike
Journal:  J Med Chem       Date:  2008-09-11       Impact factor: 7.446

4.  Effect of loperamide, a peripheral opiate agonist, on circulating glucose, free fatty acids, insulin, C-peptide and pituitary hormones in healthy man.

Authors:  R Caldara; G P Testori; C Ferrari; M Romussi; P Rampini; M Borzio; C Barbieri
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

5.  Preparation and biodistribution in mice of [11C]carfentanil: a radiopharmaceutical for studying brain mu-opioid receptors by positron emission tomography.

Authors:  H Saji; D Tsutsumi; Y Magata; Y Iida; J Konishi; A Yokoyama
Journal:  Ann Nucl Med       Date:  1992-02       Impact factor: 2.668

6.  Opioid activity and distribution of fentanyl metabolites.

Authors:  E Schneider; K Brune
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-11       Impact factor: 3.000

7.  Selective protection of stereospecific enkephalin and opiate binding against inactivation by N-ethylmaleimide: evidence for two classes of opiate receptors.

Authors:  J R Smith; E J Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

8.  Effect of loperamide and naloxone on gastric acid secretion in healthy man.

Authors:  R Caldara; M Cambielli; E Masci; M Guslandi; C Barbieri; C Ferrari
Journal:  Gut       Date:  1981-09       Impact factor: 23.059

9.  Difenoxin and loperamide: studies on possible mechanisms of intestinal antisecretory action.

Authors:  A De Luca; I M Coupar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-02       Impact factor: 3.000

10.  Naloxone inhibits the anti-diarrhoeal activity of loperamide.

Authors:  M F Piercey; M J Ruwart
Journal:  Br J Pharmacol       Date:  1979-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.